Asterias Biotherapeutics (AST) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts AST Hot Sheet
Join SI Premium – FREE
Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.20), $0.05 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $2.5 million.
For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- The LGL Group (LGL) Misses Q2 EPS by 8c
- InspireMD (NSPR) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
